Developer docs
API playgroundTry for free, no card

Search company profiles

Translational Drug Development

Full company profile

uuid00074xy

Namestring
Translational Drug Development
Legal namestring
Translational Drug Development, LLC
Websiteurl
td2inc.com
Company typeenum
Private
Founded yearint
2003
Descriptiontext

Translational Drug Development (TD2) is a privately held oncology-focused Contract Research Organization (CRO) founded in 2003 and headquartered in Scottsdale, Arizona. The company provides integrated drug development services to biotech and pharmaceutical companies developing cancer therapies, spanning four core service pillars: Clinical Trial Services (Phase I-III design, execution, and site management), Preclinical Services (over 400 proprietary cancer models including PDX, syngeneic, orthotopic, humanized, and CDX systems), Regulatory Support (IND filings, specialty designations, and FDA interactions), and Flow Cytometry (high-throughput immunophenotyping and biomarker assays). TD2 also offers PK/ADME, pharmacovigilance, medical monitoring, data management, and the Peak Partners site network for accelerated patient enrollment.

The company's underlying technology platform combines extensive in vivo model systems with bioanalytical capabilities (flow cytometry, metabolomics, proteomics, DMPK/ADME) and adaptive clinical trial design methodologies (rule-based, model-based, and model-assisted dose-finding approaches). TD2 serves three primary customer segments: early to mid-stage biotech companies requiring translational and clinical development support, large pharmaceutical companies seeking specialized expertise in complex modalities (radiopharmaceuticals, ADCs, CAR-T), and academic/research institutions conducting oncology research programs.

TD2 operates a professional services, fee-for-service revenue model with custom project-based engagements and multi-year contracts, priced on a study-by-study basis. The go-to-market motion is relationship-driven enterprise field sales, supported by content marketing, webinars, podcasts, conference participation, and thought leadership publications. The company has expanded into adjacent areas including autoimmune cell therapy development (via December 2025 In Vivo CAR-T services launch) and multi-omics biomarker capabilities (via May 2026 Panome Bio partnership), while maintaining a US-centric operational footprint aligned with FDA regulatory expertise.

Short descriptiontext

Translational Drug Development (TD2) is a privately held, oncology-focused CRO founded in 2003 that provides integrated preclinical, clinical trial, regulatory, and flow cytometry services to biotech, pharmaceutical, and academic sponsors developing cancer therapies.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersScottsdale, United States
HQ citystring
Scottsdale
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
oncology CRO services, preclinical cancer models, clinical trial management, regulatory affairs consulting, flow cytometry assays
Industry3 codes
PRIMARYHLAIALAE
Clinical Development (Phase I–III Trial Design & Execution)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
SECONDARYHLAIALAF
Translational Medicine & Biomarkers
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
SECONDARYHLAAAMAB
Companion Diagnostic (CDx) Co-Development Services (biopharma partnerships, clinical strategy)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
NAICS code3 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Scientific Research and Development Services5417
  • Medical and Diagnostic Laboratories62151
SIC code2 codes
  • Services-Commercial Physical & Biological Research8731
  • Services-Medical Laboratories8071
Product category
Oncology Contract Research Services
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Oncology CRO Services
TypeProfessional Services
Description

TD2 generates revenue by providing fee-for-service oncology contract research organization services to biotech and pharma companies. Services span preclinical studies, regulatory consulting, flow cytometry, and clinical trial management, typically billed as project-based engagements or retainer arrangements for ongoing program support.

td2inc.com
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure, Supply Chain
Pricing details1 tier
1Custom project-based engagements for oncology drug development services
ModelOtherBilling cadenceMulti-year contract
Notes

No standardized pricing tiers are publicly listed. Services are scoped and quoted based on individual client programs across preclinical, regulatory, and clinical trial service lines.

td2inc.com
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 2 records shown
1Peak Partners
Description

An alliance of high-performing research sites committed to operational excellence and innovation in oncology clinical trials.

td2inc.com
+1 more record
Core offering1 text field

Translational Drug Development (TD2) is an oncology-focused contract research organization that provides integrated preclinical, regulatory, flow cytometry, and clinical trial management services to biotech and pharmaceutical companies developing cancer therapies. The company leverages a proprietary library of over 400 preclinical cancer models, high-throughput flow cytometry, adaptive trial design, and FDA regulatory expertise to translate drug candidates from preclinical studies through Phase I–III clinical trials. Services are delivered as custom, project-based engagements directly to sponsor companies in the United States.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Accelerated trial startup timelines to 6–8 weeks for site activation and first patient enrollment up to 4+ months sooner through proactive site selection and early vendor engagement.
+2 more records
Product overview1 text field

TD2 Oncology (Translational Drug Development, LLC) is an oncology-focused Contract Research Organization (CRO) offering an integrated ecosystem of drug development services. The portfolio consists of four interconnected service pillars: (1) Clinical Trial Services for Phase I-III trial design, execution, and site management; (2) Preclinical Services encompassing over 400 cancer models and bioanalytical capabilities including flow cytometry, metabolomics, and DMPK/ADME; (3) Regulatory Support for IND filings, specialty submissions, and FDA interactions; and (4) Flow Cytometry as a standalone high-throughput platform. Key service sub-products include Protocol Design, Data Management, Model Systems (PDX, syngeneic, orthotopic, humanized), Radiopharmaceutical Services, Hematologic Malignancies Services, ADC Services, and the Peak Partners site network program. The integrated approach enables sponsors to translate scientific hypotheses from lab settings into patient responses in the clinic.

Product and service23 records
1Clinical Trial Services
CategoryClinical Trial Management
Description

Phase I, II and III oncology clinical trial design, planning, and execution using a data-driven, flexible approach with innovative methods for capturing and analyzing data to identify early signals of response. Includes study design, protocol development, site management, biostatistics, data management, pharmacovigilance, medical monitoring, eTMF, and quality assurance. Target customers: biotech and pharmaceutical companies developing oncology therapeutics.

2Preclinical Services
CategoryPreclinical Research
Description

Extensive preclinical suite including over 400 cancer models (syngeneic, orthotopic, PDX, humanized, CDX, diet-induced obesity, and adoptive cell therapy models) and bioanalytical services such as preclinical flow cytometry, metabolomics, proteomics, DMPK/ADME, in vivo and in vitro characterization, optical imaging, and ADC therapeutic evaluation. Target customers: oncology drug developers needing translational preclinical support.

3Regulatory Support
CategoryRegulatory Affairs Consulting
Description

Veteran regulatory team providing IND readiness assessment, program evaluation, IND development and filings, regulatory and medical writing, gap analysis and roadmap development, expert panel discussions, full program management and consulting, program budget and timeline executive planning, trial enablement, and FDA interactions for oncology programs. Target customers: biotech and pharmaceutical sponsors preparing regulatory submissions.

4Flow Cytometry Services
CategoryBioanalytical Services
Description

Standalone high-throughput flow cytometry platform supporting diverse assays and cell types with advanced immunophenotyping capabilities to uncover drug mechanism of action and pharmacodynamics. Includes preclinical and clinical flow cytometry services. Target customers: oncology drug developers and cell therapy developers needing flow-based biomarker and release assays.

5PK/ADME Services
CategoryBioanalytical Services
Description

Pharmacokinetics and absorption, distribution, metabolism, and excretion (PK/ADME) services for oncology drug development, supporting preclinical characterization and clinical pharmacology. Target customers: biotech and pharmaceutical sponsors developing oncology drug candidates.

6Patient Identification and Site Engagement
CategoryClinical Trial Management
Description

Strategic patient recruitment and site activation services leveraging oncology specialization, real-world data, and the Peak Partners high-performing site network to reduce recruitment timelines and enhance site collaboration. Target customers: sponsors of oncology clinical trials seeking faster patient enrollment.

7Protocol Design
CategoryClinical Trial Management
Description

Clinical trial protocol development by oncology specialists with expertise in clinical pharmacology, pharmacokinetics, and diverse cancer indications, covering dosage forms and study designs. Target customers: biotech and pharmaceutical sponsors planning oncology trials.

8Clinical Trial Data Management
CategoryClinical Trial Management
Description

Comprehensive clinical trial data management including CRF design per CDASH standards, real-time clinical trial metrics, data quality assurance, CDISC compliance, and EDC platform flexibility. Target customers: sponsors of oncology clinical trials.

9Model Systems
CategoryPreclinical Research
Description

Preclinical tumor model portfolio including Syngeneic Tumor Models, Orthotopic Tumor Models, Patient Derived Xenograft (PDX) Models, Humanized Mouse Models, Diet-Induced Obesity Tumor Model, Adoptive Cell Therapy Models, and Cell Line Derived Xenografts Models (CDX). Target customers: oncology drug developers needing translational preclinical models.

10Bioanalytical Services
CategoryBioanalytical Services
Description

Preclinical bioanalytical services including flow cytometry, metabolomics and proteomics analysis, DMPK/ADME services, in vivo and in vitro characterization including optical imaging, and therapeutic evaluation for antibody-drug conjugates. Target customers: oncology drug developers.

11IND Filing and Submission Services
CategoryRegulatory Affairs Consulting
Description

IND compilation, eCTD publication, validation, regulatory submission, annual reports, safety reporting, and FDA regulatory point of contact services for oncology drug developers. Target customers: sponsors preparing and submitting INDs.

12Specialty Filing Services
CategoryRegulatory Affairs Consulting
Description

Pre-IND and INTERACT submissions, Orphan Drug Designation, FDA Expedited Programs including Breakthrough Therapy and Fast Track designations, and Real Time Review program submissions. Target customers: sponsors pursuing expedited regulatory pathways for oncology therapies.

13Radiopharmaceutical Clinical Trial Services
CategoryClinical Trial Management
Description

Specialized clinical trial services for radiolabeled pharmaceuticals and radiopharmaceuticals, including protocol design, regulatory navigation, and trial execution. Target customers: sponsors developing radiopharmaceutical oncology therapies.

14Hematologic Malignancies Clinical Trial Services
CategoryClinical Trial Management
Description

Comprehensive clinical trial services for hematologic malignancies including leukemia, MDS, and multiple myeloma. Target customers: sponsors of hematologic oncology drug programs.

15Antibody-Drug Conjugate Clinical Trial Services
CategoryClinical Trial Management
Description

Specialized services for antibody-drug conjugate (ADC) therapeutic development, including preclinical-to-clinical translation and clinical trial management. Target customers: sponsors developing ADC oncology therapies.

16Small Molecule Clinical Trial Services
CategoryClinical Trial Management
Description

Clinical trial services for small molecule oncology therapeutics from early phase through approval. Target customers: sponsors of small molecule oncology drug programs.

17Cancer Vaccine Development Services
CategoryClinical Trial Management
Description

Clinical development services specifically designed for cancer vaccine programs. Target customers: sponsors developing cancer vaccine immunotherapies.

18Peak Partners Site Network Program
CategoryClinical Trial Management
Description

Alliance of high-performing research sites committed to operational excellence and innovation in oncology clinical trials, fostering collaboration and accelerating timelines, including global community sites, hospitals, academic centers, and site networks. Target customers: oncology trial sponsors seeking streamlined site onboarding and accelerated patient referrals.

19Pharmacovigilance Services
CategoryClinical Trial Management
Description

Drug safety monitoring and pharmacovigilance services for oncology clinical trials. Target customers: sponsors of oncology trials requiring safety reporting and adverse event management.

20Medical Monitoring Services
CategoryClinical Trial Management
Description

Medical oversight and monitoring services for clinical trial conduct. Target customers: sponsors of oncology clinical trials requiring dedicated medical monitoring.

21eTMF Management Services
CategoryClinical Trial Management
Description

Electronic Trial Master File (eTMF) management services for regulatory compliance and document management. Target customers: sponsors of oncology trials requiring TMF maintenance.

22Quality Assurance Services
CategoryClinical Trial Management
Description

Quality assurance services ensuring compliance with regulatory requirements and study protocols. Target customers: sponsors of oncology clinical trials needing QA oversight.

23Clinical Flow Cytometry Services
CategoryBioanalytical Services
Description

Advanced clinical flow cytometry solutions including immunophenotyping, receptor occupancy assays, biomarker assay development, and GLP-compliant testing for cell therapies. Target customers: cell therapy developers requiring clinical flow cytometry support.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2026-05-27
Description

TD2 Oncology and Panome Bio announced a partnership to advance translational oncology through integrated multi-omics capabilities. The collaboration combines TD2's clinical trial management and oncology expertise with Panome Bio's multi-omics platform to provide sponsors with enhanced biomarker discovery, translational insights, and integrated analytical capabilities across clinical development programs. This partnership strengthens TD2's translational ecosystem by adding comprehensive multi-omics data integration to its existing preclinical and clinical service offerings.

Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

Peak Partners is TD2's elite network of high-performing oncology research sites, including global community sites, hospitals, academic centers, and site networks. The program fosters collaboration, accelerates timelines, and strengthens communication between TD2 and trial sites. Benefits include faster startup timelines, more effective protocol design, quicker resolution of trial obstacles, and better outcomes for patients. Sites demonstrate consistent performance in clinical research and participate through a structured partnership with TD2.

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Market position
Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Translational Drug Development

Oncology Contract Research Servicestd2inc.com

Translational Drug Development (TD2) is a privately held, oncology-focused CRO founded in 2003 that provides integrated preclinical, clinical trial, regulatory, and flow cytometry services to biotech, pharmaceutical, and academic sponsors developing cancer therapies.

What Translational Drug Development does

Translational Drug Development (TD2) is a privately held oncology-focused Contract Research Organization (CRO) founded in 2003 and headquartered in Scottsdale, Arizona. The company provides integrated drug development services to biotech and pharmaceutical companies developing cancer therapies, spanning four core service pillars: Clinical Trial Services (Phase I-III design, execution, and site management), Preclinical Services (over 400 proprietary cancer models including PDX, syngeneic, orthotopic, humanized, and CDX systems), Regulatory Support (IND filings, specialty designations, and FDA interactions), and Flow Cytometry (high-throughput immunophenotyping and biomarker assays). TD2 also offers PK/ADME, pharmacovigilance, medical monitoring, data management, and the Peak Partners site network for accelerated patient enrollment.

The company's underlying technology platform combines extensive in vivo model systems with bioanalytical capabilities (flow cytometry, metabolomics, proteomics, DMPK/ADME) and adaptive clinical trial design methodologies (rule-based, model-based, and model-assisted dose-finding approaches). TD2 serves three primary customer segments: early to mid-stage biotech companies requiring translational and clinical development support, large pharmaceutical companies seeking specialized expertise in complex modalities (radiopharmaceuticals, ADCs, CAR-T), and academic/research institutions conducting oncology research programs.

TD2 operates a professional services, fee-for-service revenue model with custom project-based engagements and multi-year contracts, priced on a study-by-study basis. The go-to-market motion is relationship-driven enterprise field sales, supported by content marketing, webinars, podcasts, conference participation, and thought leadership publications. The company has expanded into adjacent areas including autoimmune cell therapy development (via December 2025 In Vivo CAR-T services launch) and multi-omics biomarker capabilities (via May 2026 Panome Bio partnership), while maintaining a US-centric operational footprint aligned with FDA regulatory expertise.

Translational Drug Development firmographics

Firmographics
Name
Translational Drug Development
Legal name
Translational Drug Development, LLC
Website
https://td2inc.com
Company type
Private
Founded year
2003
Operating status
Operating
Headcount range
101–250 employees
Short description
Translational Drug Development (TD2) is a privately held, oncology-focused CRO founded in 2003 that provides integrated preclinical, clinical trial, regulatory, and flow cytometry services to biotech, pharmaceutical, and academic sponsors developing cancer therapies.
Ownership category
akta.pro rank

Translational Drug Development industry classification

Industry
Product category
Oncology Contract Research Services
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417), Medical and Diagnostic Laboratories (62151)
SIC
Services-Commercial Physical & Biological Research (8731), Services-Medical Laboratories (8071)
akta.pro industry
PRIMARYHLAIALAE
Clinical Development (Phase I–III Trial Design & Execution)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
SECONDARYHLAIALAF
Translational Medicine & Biomarkers
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
SECONDARYHLAAAMAB
Companion Diagnostic (CDx) Co-Development Services (biopharma partnerships, clinical strategy)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics

Keywords

  • Oncology CRO services
  • Preclinical cancer models
  • Clinical trial management
  • Regulatory affairs consulting
  • Flow cytometry assays

Where Translational Drug Development is headquartered

Location

Headquarters

HQ city
Scottsdale
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Translational Drug Development business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure, Supply Chain

Revenue model

  1. Oncology CRO Services: TD2 generates revenue by providing fee-for-service oncology contract research organization services to biotech and pharma companies. Services span preclinical studies, regulatory consulting, flow cytometry, and clinical trial management, typically billed as project-based engagements or retainer arrangements for ongoing program support.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractCustom project-based engagements for oncology drug development services

Go-to-market motion1 record

Distribution channels1 record

Marketing channels7 records

Translational Drug Development product offering

Product offering

Core offering

Translational Drug Development (TD2) is an oncology-focused contract research organization that provides integrated preclinical, regulatory, flow cytometry, and clinical trial management services to biotech and pharmaceutical companies developing cancer therapies. The company leverages a proprietary library of over 400 preclinical cancer models, high-throughput flow cytometry, adaptive trial design, and FDA regulatory expertise to translate drug candidates from preclinical studies through Phase I–III clinical trials. Services are delivered as custom, project-based engagements directly to sponsor companies in the United States.

Product overview

TD2 Oncology (Translational Drug Development, LLC) is an oncology-focused Contract Research Organization (CRO) offering an integrated ecosystem of drug development services. The portfolio consists of four interconnected service pillars: (1) Clinical Trial Services for Phase I-III trial design, execution, and site management; (2) Preclinical Services encompassing over 400 cancer models and bioanalytical capabilities including flow cytometry, metabolomics, and DMPK/ADME; (3) Regulatory Support for IND filings, specialty submissions, and FDA interactions; and (4) Flow Cytometry as a standalone high-throughput platform. Key service sub-products include Protocol Design, Data Management, Model Systems (PDX, syngeneic, orthotopic, humanized), Radiopharmaceutical Services, Hematologic Malignancies Services, ADC Services, and the Peak Partners site network program. The integrated approach enables sponsors to translate scientific hypotheses from lab settings into patient responses in the clinic.

Differentiator

Problem solved

Functional benefit

Brands

  • Peak Partners: An alliance of high-performing research sites committed to operational excellence and innovation in oncology clinical trials.
  • Dynamic Trial

Products and services

  • Clinical Trial Services Phase I, II and III oncology clinical trial design, planning, and execution using a data-driven, flexible approach with innovative methods for capturing and analyzing data to identify early signals of response. Includes study design, protocol development, site management, biostatistics, data management, pharmacovigilance, medical monitoring, eTMF, and quality assurance. Target customers: biotech and pharmaceutical companies developing oncology therapeutics.
  • Preclinical Services Extensive preclinical suite including over 400 cancer models (syngeneic, orthotopic, PDX, humanized, CDX, diet-induced obesity, and adoptive cell therapy models) and bioanalytical services such as preclinical flow cytometry, metabolomics, proteomics, DMPK/ADME, in vivo and in vitro characterization, optical imaging, and ADC therapeutic evaluation. Target customers: oncology drug developers needing translational preclinical support.
  • Regulatory Support Veteran regulatory team providing IND readiness assessment, program evaluation, IND development and filings, regulatory and medical writing, gap analysis and roadmap development, expert panel discussions, full program management and consulting, program budget and timeline executive planning, trial enablement, and FDA interactions for oncology programs. Target customers: biotech and pharmaceutical sponsors preparing regulatory submissions.
  • Flow Cytometry Services Standalone high-throughput flow cytometry platform supporting diverse assays and cell types with advanced immunophenotyping capabilities to uncover drug mechanism of action and pharmacodynamics. Includes preclinical and clinical flow cytometry services. Target customers: oncology drug developers and cell therapy developers needing flow-based biomarker and release assays.
  • PK/ADME Services Pharmacokinetics and absorption, distribution, metabolism, and excretion (PK/ADME) services for oncology drug development, supporting preclinical characterization and clinical pharmacology. Target customers: biotech and pharmaceutical sponsors developing oncology drug candidates.
  • Patient Identification and Site Engagement Strategic patient recruitment and site activation services leveraging oncology specialization, real-world data, and the Peak Partners high-performing site network to reduce recruitment timelines and enhance site collaboration. Target customers: sponsors of oncology clinical trials seeking faster patient enrollment.
  • Protocol Design Clinical trial protocol development by oncology specialists with expertise in clinical pharmacology, pharmacokinetics, and diverse cancer indications, covering dosage forms and study designs. Target customers: biotech and pharmaceutical sponsors planning oncology trials.
  • Clinical Trial Data Management Comprehensive clinical trial data management including CRF design per CDASH standards, real-time clinical trial metrics, data quality assurance, CDISC compliance, and EDC platform flexibility. Target customers: sponsors of oncology clinical trials.
  • Model Systems Preclinical tumor model portfolio including Syngeneic Tumor Models, Orthotopic Tumor Models, Patient Derived Xenograft (PDX) Models, Humanized Mouse Models, Diet-Induced Obesity Tumor Model, Adoptive Cell Therapy Models, and Cell Line Derived Xenografts Models (CDX). Target customers: oncology drug developers needing translational preclinical models.
  • Bioanalytical Services Preclinical bioanalytical services including flow cytometry, metabolomics and proteomics analysis, DMPK/ADME services, in vivo and in vitro characterization including optical imaging, and therapeutic evaluation for antibody-drug conjugates. Target customers: oncology drug developers.
  • IND Filing and Submission Services IND compilation, eCTD publication, validation, regulatory submission, annual reports, safety reporting, and FDA regulatory point of contact services for oncology drug developers. Target customers: sponsors preparing and submitting INDs.
  • Specialty Filing Services Pre-IND and INTERACT submissions, Orphan Drug Designation, FDA Expedited Programs including Breakthrough Therapy and Fast Track designations, and Real Time Review program submissions. Target customers: sponsors pursuing expedited regulatory pathways for oncology therapies.
  • Radiopharmaceutical Clinical Trial Services Specialized clinical trial services for radiolabeled pharmaceuticals and radiopharmaceuticals, including protocol design, regulatory navigation, and trial execution. Target customers: sponsors developing radiopharmaceutical oncology therapies.
  • Hematologic Malignancies Clinical Trial Services Comprehensive clinical trial services for hematologic malignancies including leukemia, MDS, and multiple myeloma. Target customers: sponsors of hematologic oncology drug programs.
  • Antibody-Drug Conjugate Clinical Trial Services Specialized services for antibody-drug conjugate (ADC) therapeutic development, including preclinical-to-clinical translation and clinical trial management. Target customers: sponsors developing ADC oncology therapies.
  • Small Molecule Clinical Trial Services Clinical trial services for small molecule oncology therapeutics from early phase through approval. Target customers: sponsors of small molecule oncology drug programs.
  • Cancer Vaccine Development Services Clinical development services specifically designed for cancer vaccine programs. Target customers: sponsors developing cancer vaccine immunotherapies.
  • Peak Partners Site Network Program Alliance of high-performing research sites committed to operational excellence and innovation in oncology clinical trials, fostering collaboration and accelerating timelines, including global community sites, hospitals, academic centers, and site networks. Target customers: oncology trial sponsors seeking streamlined site onboarding and accelerated patient referrals.
  • Pharmacovigilance Services Drug safety monitoring and pharmacovigilance services for oncology clinical trials. Target customers: sponsors of oncology trials requiring safety reporting and adverse event management.
  • Medical Monitoring Services Medical oversight and monitoring services for clinical trial conduct. Target customers: sponsors of oncology clinical trials requiring dedicated medical monitoring.
  • eTMF Management Services Electronic Trial Master File (eTMF) management services for regulatory compliance and document management. Target customers: sponsors of oncology trials requiring TMF maintenance.
  • Quality Assurance Services Quality assurance services ensuring compliance with regulatory requirements and study protocols. Target customers: sponsors of oncology clinical trials needing QA oversight.
  • Clinical Flow Cytometry Services Advanced clinical flow cytometry solutions including immunophenotyping, receptor occupancy assays, biomarker assay development, and GLP-compliant testing for cell therapies. Target customers: cell therapy developers requiring clinical flow cytometry support.

Quantifiable outcome

  • Accelerated trial startup timelines to 6–8 weeks for site activation and first patient enrollment up to 4+ months sooner through proactive site selection and early vendor engagement.
  • +2 more outcomes

Companies that use Translational Drug Development

Customer profile

Segments3 records

Ideal customer profiles3 records

Translational Drug Development technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature6 records

Translational Drug Development partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core.

  • Panome BiocoreTechnology or Integration · 27 May 2026TD2 Oncology and Panome Bio announced a partnership to advance translational oncology through integrated multi-omics capabilities. The collaboration combines TD2's clinical trial management and oncology expertise with Panome Bio's multi-omics platform to provide sponsors with enhanced biomarker discovery, translational insights, and integrated analytical capabilities across clinical development programs. This partnership strengthens TD2's translational ecosystem by adding comprehensive multi-omics data integration to its existing preclinical and clinical service offerings.
  • Peak Partners NetworkcoreChannel Partner/ Reseller/ DistributorPeak Partners is TD2's elite network of high-performing oncology research sites, including global community sites, hospitals, academic centers, and site networks. The program fosters collaboration, accelerates timelines, and strengthens communication between TD2 and trial sites. Benefits include faster startup timelines, more effective protocol design, quicker resolution of trial obstacles, and better outcomes for patients. Sites demonstrate consistent performance in clinical research and participate through a structured partnership with TD2.

Scale indicators5 records

Recent moves5 records

Expansion highlights5 records

Translational Drug Development competitors and assessment

Company assessment

Market position

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

Translational Drug Development social profiles

Digital presence

Translational Drug Development financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Translational Drug Development leadership team

Management profile

Number of profiles

Profiles4 records

Translational Drug Development funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Translational Drug Development M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Translational Drug Development

What does Translational Drug Development do?

Translational Drug Development (TD2) is an oncology-focused contract research organization that provides integrated preclinical, regulatory, flow cytometry, and clinical trial management services to biotech and pharmaceutical companies developing cancer therapies. The company leverages a proprietary library of over 400 preclinical cancer models, high-throughput flow cytometry, adaptive trial design, and FDA regulatory expertise to translate drug candidates from preclinical studies through Phase I–III clinical trials. Services are delivered as custom, project-based engagements directly to sponsor companies in the United States.

Is Translational Drug Development a public or private company?

Translational Drug Development is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Translational Drug Development founded?

Translational Drug Development was founded in 2003. It employs 101 to 250 people.

Where is Translational Drug Development based?

Translational Drug Development is headquartered in Scottsdale, United States, in the North America region.

How does Translational Drug Development make money?

One revenue line is on record: oncology CRO Services.

Does Translational Drug Development have an API?

No public API is recorded for Translational Drug Development.

What industry is Translational Drug Development in?

Translational Drug Development's product category is Oncology Contract Research Services. Its primary akta.pro industry code is HLAIALAE, Clinical Development (Phase I–III Trial Design & Execution), with a secondary code of HLAIALAF, Translational Medicine & Biomarkers. Its NAICS code is 541714 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
GlobeNewswireLaidlaw Venture Partners Portfolio Company Voltron Therapeutics Enters into Strategic Development Agreement With Translational Drug Development (TD2), a Precision Oncology Contract Research OrganizatiVoltron Therapeutics, a portfolio company of Laidlaw Venture Partners, entered a strategic development agreement with TD2, a precision oncology CRO. The partnership will evaluate the VaxCelerate vaccine platform across tumor settings, starting with ovarian cancer, to support Voltron's initial BLA submission.Business Wire BlogRCT Acquires Translational Drug Development, LLCResearch Corporation Technologies (RCT) acquired Translational Drug Development (TD2) and invested growth capital into the oncology-focused drug development firm. TD2, based in Scottsdale, Arizona, provides translational preclinical services, regulatory guidance, and clinical trial design. RCT plans to expand TD2's capabilities to support early-stage and proof-of-concept programs.GlobeNewswirePharmaCyte Executives Meet With Translational Drug Development to Advance Pancreatic Cancer Clinical TrialPharmaCyte Biotech executives met TD2 to discuss its pancreatic cancer clinical trial design and IND filing. The trial will compare PharmaCyte's microcapsule treatment with capecitabine plus radiation, with multiple U.S. and international sites. TD2 and Chamow will prepare the IND's CMC section.GlobeNewswirePharmaCyte Biotech Management Interviewed to Discuss Key Aspects of New Pancreatic Cancer Clinical Trial DesignPharmaCyte Biotech released an interview with CEO Kenneth L. Waggoner and COO Dr. Gerald W. Crabtree discussing its new pancreatic cancer clinical trial design. The trial was moved to the United States under Translational Drug Development (TD2), and the interview covers the company's efforts to address an unmet medical need with its encapsulated live-cell treatment.GlobeNewswireNuvilex Begins Preclinical Studies With Translational Drug Development to Determine if Nuvilex's Unique Cancer Treatment Can Slow Accumulation of Malignant Ascites FluidNuvilex began preclinical studies at TD2 to test its cancer treatment on malignant ascites fluid in mice. The studies use human ovarian cancer cells and compare treatment groups, including Nuvilex's Cell-in-a-Box encapsulated cells with ifosfamide. The company expects this to be the beginning of its development journey.GlobeNewswireNuvilex Provides Update on Status of Preclinical Studies at Translational Drug DevelopmentNuvilex announced that encapsulated cells for its preclinical studies have arrived in the U.S., and the studies will begin at TD2 in Scottsdale, Arizona, the week of August 18, 2014. The studies aim to test if the company's treatment can slow fluid accumulation in abdominal tumors, including pancreatic cancer.GlobeNewswireInform Genomics and Translational Drug Development (TD2) Announce Strategic CollaborationInform Genomics and TD2 announced a strategic collaboration to combine Inform Genomics' genomic analytics with TD2's oncology drug development services. The partnership aims to predict side effects and identify subpopulations at risk during clinical trials. Inform Genomics' lead program includes OnPART and HSCT/Mucositis products in development.GlobeNewswireNuvilex and Translational Drug Development (TD2) Begin Preparations for US-Based Studies on Symptoms Associated With Pancreatic CancerNuvilex and TD2 have begun preparations for US preclinical and clinical studies on pain and ascites in advanced pancreatic cancer. The studies aim to test Nuvilex's ifosfamide-based treatment, separate from an Australian Phase 2b trial. Preclinical studies are planned to start shortly.GlobeNewswireNuvilex Selects Translational Drug Development (TD2) to Advance Treatment for Pancreatic CancerNuvilex signed a Master Services Agreement with TD2 to conduct preclinical and clinical studies for its pancreatic cancer treatment using Cell-in-a-Box technology. TD2's Pancreatic Cancer Research Team will organize and accelerate clinical development, with about 65 clinicians and 45 sites. The partnership aims to advance the treatment combining ifosfamide and encapsulated live cells.